Only early intervention with gamma-aminobutyric acid cell therapy is able to reverse neuropathic pain after partial nerve injury

Journal of Neurotrauma
L A StubleyM J Eaton

Abstract

Pharmacological treatment for neuropathic pain, although often effective for brief periods, can result in intractable persistent pain with certain patients. Cell therapy for neuropathic pain is a newly developing technology useful for an examination of enhanced normal sensory function after nerve injury with the placement of cells near the spinal cord, and grafts of immortalized cells bioengineered to chronically supply the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) have been used to reverse the chronic pain behaviors. However, it is not known whether there is a therapeutic window for the use of intervention with cell therapy after partial nerve injury. To investigate whether neuropathic pain is sensitive to the timing of placement of cell grafts, neuronal cells bioengineered to synthesize GABA were transplanted in the lumbar subarachnoid space one to four weeks after unilateral chronic constriction injury (CCI) of the sciatic nerve and sensory behaviors were evaluated before and after CCI and transplants. Both thermal hyperalgesia and tactile allodynia were reversed when transplants were placed either one or two weeks after partial nerve injury, compared to maintenance of these behaviors with the injury alone. ...Continue Reading

References

Jan 1, 1989·Neuroscience·A J Todd, J McKenzie
Jun 1, 1988·Experimental Neurology·W S KingeryJ D Kocsis
Mar 1, 1980·The Journal of Pharmacy and Pharmacology·G A JohnstonC G Freeman
Feb 1, 1984·British Journal of Pharmacology·M DésarmenienR Schlichter
Dec 1, 1994·British Journal of Pharmacology·M Malcangio, N G Bowery
Aug 27, 1993·Brain Research·J M Castro-LopesA Coimbra
Apr 6, 1993·European Journal of Pharmacology·D L Hammond, J D Washington
Jan 1, 1995·Acta Neurochirurgica. Supplement·Y LazorthesC Caratero
Oct 1, 1996·Journal of Pain and Symptom Management·P G Loubser, N M Akman
Oct 1, 1996·Journal of Neurophysiology·G S HollrigelI Soltesz
Jan 1, 1995·Stereotactic and Functional Neurosurgery·T TairaK Takakura
Dec 1, 1996·Trends in Pharmacological Sciences·M Malcangio, N G Bowery
Jan 1, 1999·Electroencephalography and Clinical Neurophysiology·T FakhouryB Blumenkopf
Dec 10, 1999·Neuropharmacology·K E McCarson, S J Enna
Apr 13, 2000·Journal of Pain and Symptom Management·K A Follett, C P Naumann

❮ Previous
Next ❯

Citations

Oct 8, 2008·Neuroscience Bulletin·Yan Liu, Hong-Yun Huang
Oct 3, 2002·European Journal of Pharmacology·Rachael M NelsonAtticus H Hainsworth
Jan 27, 2009·Brain Research Reviews·Theodore J PriceSteven A Prescott
Jun 30, 2012·Pain Research and Treatment·Mary J EatonEva Widerström-Noga
Jul 2, 2010·European Journal of Pain : EJP·Michiel TruinElbert A J Joosten
Sep 27, 2014·Neuroscience·D Guo, J Hu
Jul 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jun LiuDavid J Fink
Mar 11, 2017·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Min Ju LeeKyung Sun Kang
Sep 3, 2013·Cell Transplantation·Lin ChenPaul R Sanberg
Apr 4, 2009·Physiological Reviews·Jürgen Sandkühler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.